

Flerie AB's Nomination Committee for the 2026 Annual General Meeting

The Nomination Committee, which has been appointed in accordance with the principles adopted by the General Meeting on June 10, 2024, consists of:

- Thomas Eldered appointed by T&M Participation AB and T&M Förvaltning AB
- Jannis Kitsakis appointed by the Fourth Swedish National Pension Fund
- Lars Backsell appointed by Cajelo Invest Ltd

Shareholders having appointed members to the Nomination Committee represent 85.8 percent of the voting rights for all shares of Flerie AB, as of September 30, 2025. Jannis Kitsakis is appointed Chairman of the Nomination Committee. Thomas Eldered is also adjunct in his role as the Chairman of the Board.

The Annual General Meeting 2026 will be held on March 26, 2026. Shareholders who would like to submit proposals to the Nomination Committee can do so by e-mail to nomination.committee@flerie.com. Proposals have to be received no later than January 10, 2026, to be considered by the Nomination Committee.

For more information:

Ted Fjällman, CEO

Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

[Flerie AB's Nomination Committee for the 2026 Annual General Meeting](#)